These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12624709)

  • 1. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
    Nakamura N; Hamazaki T; Johkaji H; Minami S; Yamazaki K; Satoh A; Sawazaki S; Urakaze M; Kobayashi M; Osawa H; Yamabe H; Okomura K
    Clin Exp Med; 2003 Feb; 2(4):180-4. PubMed ID: 12624709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
    Ikewaki K; Mochizuki K; Iwasaki M; Nishide R; Mochizuki S; Tada N
    Metabolism; 2002 Oct; 51(10):1348-54. PubMed ID: 12370857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of eicosapentaenoic acids on remnant-like particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus.
    Nakamura N; Hamazaki T; Kobayashi M; Ohta M; Okuda K
    In Vivo; 1998; 12(3):311-4. PubMed ID: 9706476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.
    Ahn CW; Lee HC; Park SW; Song YD; Huh KB; Oh SJ; Kim YS; Choi YK; Kim JM; Lee TH
    Diabetes Res Clin Pract; 2001 Apr; 52(1):45-53. PubMed ID: 11182215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
    Vaverková H; Chlup R; Ficker L; Novotny D; Bartek J
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():74-7. PubMed ID: 9288551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
    Mitsuhashi N; Tanaka Y; Kubo S; Ogawa S; Hayashi C; Uchino H; Shimizu T; Watada H; Kawasumi M; Onuma T; Kawamori R
    Endocr J; 2004 Dec; 51(6):545-50. PubMed ID: 15644572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.
    Tani T; Uehara K; Sudo T; Marukawa K; Yasuda Y; Kimura Y
    Atherosclerosis; 2000 Oct; 152(2):299-305. PubMed ID: 10998457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
    Rizzo M; Corrado E; Patti AM; Rini GB; Mikhailidis DP
    Expert Opin Pharmacother; 2011 Mar; 12(4):647-55. PubMed ID: 21284580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
    Agrawal NK; Maiti R; Dash D; Pandey BL
    Pharmacol Res; 2007 Aug; 56(2):118-23. PubMed ID: 17548203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol and peripheral arterial disease.
    Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
    Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I.
    Zenobi PD; Holzmann P; Glatz Y; Riesen WF; Froesch ER
    Diabetologia; 1993 May; 36(5):465-9. PubMed ID: 8314453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
    Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.